OTD provides independent consulting services in oncology early drug development.
We offer integrated drug discovery services and routinely conduct contract preclinical research.
The OTD team has collective experience managing over 50 Phase I-II oncology clinical trials.
A CRO focused solely on oncology, specialized in the early development of single agent and combination anticancer regimens.
Our goal is to support our partners to establish a clinical development plan to generate data in a timely, efficient and cost-effective manner.
The BET Bromodomain Inhibitor OTX015 Affects Pathogenetic Pathways in Preclinical B-cell Tumor Models and Synergizes with Targeted Drugs
Boi M, Gaudio E, Bonetti P, Kwee I, Bernasconi E, Tarantelli C, Rinaldi A, Testoni M, Cascione L, Ponzoni M, Mensah AA, Stathis A, Stussi G, Riveiro ME, Herait P, Inghirami G, Cvitkovic E, Zucca E, Bertoni F.
Clin Cancer Res. 2015 Jan 26.
100 rue Martre
92110 Clichy - FRANCE
Tel: +33 1 47 15 01 01
Fax: +33 1 45 19 06 59